Determining whether Tempus AI is undervalued depends on how investors weigh its high growth rates against its premium valuation multiples. Proponents argue that its unique market positioning in precision oncology, vast multimodal clinical database, and expanding AI diagnostic tools justify its valuation. Conversely, cautious analysts point out that high price-to-sales multiples leave little room for execution errors, making comprehensive fundamental research essential before drawing conclusions.